Case Reports Open access

Development of thymoma without myasthenia gravis in a patient with radiographic axial spondyloarthritis treated with tumor necrosis factor-α inhibitors

Authors

Published
5 June 2025
Section
Case Reports

Abstract

Thymic tumors are rare in the general population, and to the best of our knowledge, no cases of thymoma have been described in patients with rheumatic diseases treated with tumor necrosis factor (TNF)-α inhibitors, except for the case of a patient receiving infliximab for Crohn’s disease (CD) who developed a B2 thymoma. We describe a 60-year-old Caucasian male with radiographic axial spondyloarthritis (r-axSpA) and CD who developed an AB-type thymoma without myasthenia gravis after 18 years of treatment with TNF-α inhibitors. The patient had received the same molecule since the r-axSpA/CD diagnosis and changed it 6 months before the diagnosis of thymoma due to a disease flare. At the time of the drug switch, no mediastinal mass was present on the chest X-ray. The thymoma was surgically removed, and no additional therapy was needed. Treatment with TNF-α inhibitors was reintroduced after surgery. This case raises some important questions that remain open and deserve to be addressed in the future, such as the association between immunosuppressive therapy and thymoma and the controversial relationship between TNF-α inhibitors and myasthenia gravis.

References

  1. Marx A, Chan JKC, Chalabreysse L, Dacic S, Detterbeck F, French CA, et al. The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors? J Thorac Oncol 2022; 17: 200-13. DOI: https://doi.org/10.1016/j.jtho.2021.10.010
  2. Huss V, Bower H, Hellgren K, Frisell T, Asklling J. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. Ann Rheum Dis 2023; 82: 911-9. DOI: https://doi.org/10.1136/ard-2022-223636
  3. Seror R, Lafourcade A, De Rycke Y, Pinto S, Castaneda J, Fautrel B, et al. Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database. RMD Open 2022; 8: e002139. DOI: https://doi.org/10.1136/rmdopen-2021-002139
  4. Konso M, El Bacha H, Dilal S, Mendes P, Znati K, Benzzoubeir N, et al. Development of thymoma during anti-TNF alpha therapy: coincidence or consequence. IAR J Med Cse Rep 2023; 4: 19-21.
  5. Rich AL. Epidemiology of thymoma. J Thorac Dis 2020; 12: 7531-5. DOI: https://doi.org/10.21037/jtd-2019-thym-02
  6. Blum TG, Misch D, Kollmeier J, Thiel S, Bauer TT. Autoimmune disorders and paraneoplastic syndromes in thymoma. J Thorac Dis 2020; 12: 7571-90. DOI: https://doi.org/10.21037/jtd-2019-thym-10
  7. Souadjian JV, Enriquez P, Silverstein MN, Pepin JM. The spectrum of diseases associated with thymoma. Arch Intern Med 1974; 134: 374-9. DOI: https://doi.org/10.1001/archinte.1974.00320200184029
  8. Teramatsu T, Yamamoto H, Matsutani Y. Mediastinal tumors in Japan survey. Jpn J Thorac Surg 1976; 24: 270-3.
  9. Okubo K, Kondo N, Okamoto T, Isobe J, Ueno Y. Excision of an invasive thymoma: a cure for ulcerative colitis? Case Reports Ann Thorac Surg 2001; 71: 2013-5. DOI: https://doi.org/10.1016/S0003-4975(00)02501-7
  10. De Rosa A, Fornili M, Maestri Tassoni M, Guida M, Baglietto L, Petrucci L, et al. Thymoma-associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma. Thorac Cancer 2021; 12: 106-13. DOI: https://doi.org/10.1111/1759-7714.13724
  11. Berrih-Aknin S, Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun 2014; 52: 90-100. DOI: https://doi.org/10.1016/j.jaut.2013.12.011
  12. Garcia-Carrasco M, Escarcega RO, Fuentes-Alexandro S, Riebeling C, Cervera R. Therapeutic options in autoimmune myasthenia gravis. Autoimmun Rev 2007; 6: 373-8. DOI: https://doi.org/10.1016/j.autrev.2007.01.001
  13. Rodolico C, Nicocia G, Damato V, Antonini G, Liguori R, Evoli A. Benefit and danger from immunotherapy in myasthenia gravis. Neurol Sci 2021; 42: 1367-75. DOI: https://doi.org/10.1007/s10072-021-05077-6
  14. Lee JS, Joo IS, Seok JI. Widely varying TNF-alpha levels in patients with myasthenia gravis Neurol Sci 2009; 30: 259-62. DOI: https://doi.org/10.1007/s10072-009-0023-0
  15. Bruzzese V, Marrese C, Scolieri P, Hassan C, Lorenzetti R, Zullo A. Myasthenia gravis onset during rheumatic disease: a new paradoxical effect of anti-TNF alpha therapy? Int J Rheum Dis 2015; 18: 375-6. DOI: https://doi.org/10.1111/1756-185X.12340
  16. Nicocia G, Bonanno C, Lupica A, Toscano A, Rodolico C. Myasthenia gravis after etanercept and ustekinumab treatment for psoriatic arthritis: a case report. Neuromuscul Disord 2020; 30: 246-9. DOI: https://doi.org/10.1016/j.nmd.2020.01.001
  17. Pelechas E, Memi T, Markatseli TE, Voulgari PV, Drosos AA. Adalimumab-induced myasthenia gravis: case-based review. Rheumatol Int 2020; 40: 1891-4. DOI: https://doi.org/10.1007/s00296-020-04587-4

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.